サポート ブログ Top 10 Antibody Drug Approvals from FDA 1980-2022

Top 10 Antibody Drug Approvals from FDA 1980-2022

Biointron 2023-12-18 Read time: 4 mins
Top 10 Antibody Drugs Approval from FDA 1980-2022
Image credit: Sarah Silbiger/Getty Images

Antibody drugs have become an increasingly important class of therapeutics for a wide range of diseases. In this article, we will introduce the top 10 antibody drugs that have been approved by regulatory agencies from 1980 to 2022 and provide some information about their development history and the diseases they are used to treat.

  1. Humira (adalimumab): Humira was approved by the FDA in 2002 and is used to treat rheumatoid arthritis, psoriasis, and other autoimmune disorders. It was the first fully human antibody drug approved by the FDA.

  2. Keytruda (pembrolizumab): Keytruda was approved by the FDA in 2014 and is used to treat melanoma, lung cancer, and other cancers. It was the first PD-1 inhibitor approved by the FDA.

  3. Herceptin (trastuzumab): Herceptin was approved by the FDA in 1998 and is used to treat HER2-positive breast cancer. It was the first monoclonal antibody drug approved for cancer treatment.

  4. Remicade (infliximab): Remicade was approved by the FDA in 1998 and is used to treat Crohn's disease, rheumatoid arthritis, and other autoimmune disorders. It was the first anti-TNF-alpha antibody drug approved by the FDA.

  5. Rituxan (rituximab): Rituxan was approved by the FDA in 1997 and is used to treat non-Hodgkin's lymphoma and other blood cancers. It was the first monoclonal antibody drug approved for cancer treatment.

  6. Opdivo (nivolumab): Opdivo was approved by the FDA in 2014 and is used to treat melanoma, lung cancer, and other cancers. It was the first PD-1 inhibitor approved by the FDA.

  7. Avastin (bevacizumab): Avastin was approved by the FDA in 2004 and is used to treat colon cancer, lung cancer, and other cancers. It was the first anti-angiogenic antibody drug approved by the FDA.

  8. Lucentis (ranibizumab): Lucentis was approved by the FDA in 2006 and is used to treat macular degeneration, diabetic retinopathy, and other eye diseases. It was the first antibody drug approved for ophthalmic use.

  9. Stelara (ustekinumab): Stelara was approved by the FDA in 2009 and is used to treat psoriasis, psoriatic arthritis, and Crohn's disease. It was the first interleukin inhibitor approved by the FDA.

  10. Tecentriq (atezolizumab): Tecentriq was approved by the FDA in 2016 and is used to treat bladder cancer, lung cancer, and other cancers. It was the first PD-L1 inhibitor approved by the FDA.

At Biointron, we offer high-quality recombinant antibody production services that can help researchers and biotech companies develop antibody-based drugs for various diseases. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.


Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。